First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies

被引：0
|
作者：
Smith, J. [1 ]
Urosevic, J. [1 ]
Moore, S. [1 ]
Magiera, L. [1 ]
Bradshaw, L. [1 ]
Gianni, D. [2 ]
Srinivasan, B. [2 ]
Debreczeni, J. [2 ]
Stubbs, C. [2 ]
Vazquez-Chantada, M. [2 ]
Hong, T. [3 ]
Cronin, A. [1 ]
Khan, K. [1 ]
Wiseman, E. [1 ]
Ferguson, D. [3 ]
Lynch, J. [1 ]
Chan, H. M. [3 ]
Critchlow, S. [1 ]
Fawell, S. [3 ]
Dean, E. [1 ]
机构：
[1] AstraZeneca, Res & Early Dev Oncol R&D, Cambridge, England
[2] AstraZeneca, Discovery Sci Biopharmaceut R&D, Cambridge, England
[3] AstraZeneca, Res & Early Dev Oncol R&D, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB134
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 32 条
  • [21] TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors
    Briggs, Kimberly J.
    Tsai, Alice
    Zhang, Minjie
    Tonini, Matthew R.
    Haines, Brian
    Huang, Alan
    Cottrell, Kevin M.
    CANCER RESEARCH, 2023, 83 (07)
  • [22] PH020-803: an MTA-cooperative and brain-penetrable PRMT5 inhibitor that selectively targets MTAP-deleted tumors
    Gao, Feng
    Liu, Bin
    Jing, Liandong
    Wu, Yongyong
    Zhang, Pengzhi
    Yuan, Shuai
    Zhao, Hui
    Gao, Yu
    Li, Zhizhong
    Wang, Xiaofan
    Guo, Yongqi
    CANCER RESEARCH, 2023, 83 (07)
  • [23] MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Induces Cell Cycle Arrest and Synergizes With Oxaliplatin and Gemcitabine for Enhanced Anticancer Effects
    Soeta, Toshihiro
    Sugisawa, Norihiko
    Yamamura, Akihiro
    Tanaka, Naoki
    Imoto, Hirofumi
    Tsuchiya, Takahiro
    Aizawa, Takashi
    Okamoto, Koji
    Kawamura, Mari
    Saijo, Fumito
    Mizuma, Masamichi
    Ohnuma, Shinobu
    Kamei, Takashi
    Unno, Michiaki
    ANTICANCER RESEARCH, 2024, 44 (12) : 5231 - 5240
  • [24] Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers
    Cottrell, Kevin M.
    Briggs, Kimberly J.
    Whittington, Douglas A.
    Jahic, Haris
    Ali, Janid A.
    Davis, Charles B.
    Gong, Shanzhong
    Gotur, Deepali
    Gu, Lina
    McCarren, Patrick
    Tonini, Matthew R.
    Tsai, Alice
    Wilker, Erik W.
    Yuan, Hongling
    Zhang, Minjie
    Zhang, Wenhai
    Huang, Alan
    Maxwell, John P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) : 6064 - 6080
  • [25] TNG908, A BRAIN-PENETRANT MTA-COOPERATIVE PRMT5 INHIBITOR, IS EFFICACIOUS IN PRECLINICAL MTAP-DELETED MODELS INCLUDING GLIOBLASTOMA
    Zhang, Minjie
    Tsai, Alice
    Cottrell, Kevin
    Wilker, Erik
    Davis, Charles
    DiBenedetto, Heather
    Weitzman, Ron
    Huang, Alan
    Maxwell, John
    Briggs, Kimberly
    NEURO-ONCOLOGY, 2023, 25
  • [26] TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors
    Briggs, K.
    Tsai, A.
    Zhang, M.
    Tonini, M.
    Haines, B.
    Huang, A.
    Cottrell, K.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S84 - S84
  • [27] MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models
    Smith, Christopher R.
    Engstrom, Lars D.
    Kulyk, Svitlana
    Aranda, Ruth
    Waters, Laura
    Moya, Krystal
    Bowcut, Victoria
    Hebbert, Allan
    Trinh, David
    Briere, David M.
    Lawson, J. David
    Clarine, Jeff
    Rahbaek, Lisa
    Christensen, James G.
    Marx, Matthew A.
    Olson, Peter
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [28] Combination of MTA-cooperative PRMT5 inhibitor and direct mutant-selective KRAS inhibitors as a novel therapeutic approach for MTAP-deficient pancreatic cancer
    Drizyte-Miller, Kristina
    Chang, Wen-Hsuan
    Waters, Andrew M.
    Stalnecker, Clint A.
    Wang, Junning
    Aguirre, Andrew J.
    Cox, Adrienne D.
    Der, Channing J.
    CANCER RESEARCH, 2024, 84 (06)
  • [29] First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration5
    Rodon, J.
    Prenen, H.
    Sacher, A.
    Villalona-Calero, M.
    Penel, N.
    El Helali, A.
    Rottey, S.
    Yamamoto, N.
    Ghiringhelli, F.
    Goebeler, M. E.
    Doi, T.
    Postel-Vinay, S.
    Lin, C. -c.
    Liu, C.
    Chuang, C. -h.
    Keyvanjah, K.
    Eggert, T.
    Neil, B. h. o '
    ANNALS OF ONCOLOGY, 2024, 35 (12) : 1138 - 1147
  • [30] PH020-2: an MTA-cooperative PRMT5 inhibitor with excellent selectivity and brain-penetration capability that targets MTAP-deleted tumors
    Gao, Feng
    Liu, Bin
    Wang, Jing
    Jing, Liandong
    Wu, Yongyong
    Zhang, Pengzhi
    Gao, Yu
    Li, Zhizhong
    Guo, Yongqi
    CANCER RESEARCH, 2024, 84 (06)
1234